Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises EQT Infrastructure portfolio company IP-Only in connection with its acquisition of Trelleborgs Stadsnät
Mandate

Vinge advises EQT Infrastructure portfolio company IP-Only in connection with its acquisition of Trelleborgs Stadsnät

June 22, 2020 Employment and Benefits Commercial Agreements Real Estate and Construction M&A

Vinge has advised IP-Only in connection with entering into an agreement to acquire 100% of the shares in Trelleborgs Stadsnät AB.

Trelleborgs Stadsnät AB was established in 2012 and owns and operates open fiber network in the Municipality of Trelleborg with a large customer base, consisting of households and enterprises.

Vinge’s team consisted of Daniel Rosvall, Karl Klackenberg and Milad Kamali (M&A), Mathilda Persson (Commercial Agreements), Kristoffer Larson (Real Property) and Ebba Svenburg (Employment).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024